Drug delivery medical device
First Claim
1. A medical device comprising:
- a balloon; and
a coating on at least a portion of the balloon,wherein the coating comprises a polymer, a macrolide immunosuppressive drug in crystalline form present on an exterior surface of the coating and a cationic binding agent, andwherein the device releases at least 3% of the active agent to a treatment site upon inflation of the balloon in vivo.
7 Assignments
0 Petitions
Accused Products
Abstract
Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
-
Citations
20 Claims
-
1. A medical device comprising:
-
a balloon; and a coating on at least a portion of the balloon, wherein the coating comprises a polymer, a macrolide immunosuppressive drug in crystalline form present on an exterior surface of the coating and a cationic binding agent, and wherein the device releases at least 3% of the active agent to a treatment site upon inflation of the balloon in vivo. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
-
16. A method comprising
providing a device comprising a balloon; - and a coating on at least a portion of the balloon, wherein the coating comprises a polymer, a macrolide immunosuppressive drug in crystalline form present on an exterior surface of the coating and a cationic binding agent, and
inflating the balloon of the device in an artery in vivo, wherein upon inflating the balloon at least 3% of the active agent is transferred to tissue of the artery in vivo. - View Dependent Claims (17, 18)
- and a coating on at least a portion of the balloon, wherein the coating comprises a polymer, a macrolide immunosuppressive drug in crystalline form present on an exterior surface of the coating and a cationic binding agent, and
-
19. A method of coating at least a portion of a medical device comprising a balloon, thereby forming on the medical device a coating on the balloon comprising an active agent and a cationic binding agent, wherein the method comprises:
-
a. dissolving the binding agent to form a binding agent solution, b. combining the binding agent solution and the active agent, c. mixing the combined binding agent and active agent using a high shear mixer, d. forming a suspension comprising the combined mixed active agent and binding agent, e. lyophilising the suspension to form a lyophilisate of the active agent and the binding agent, and f. coating the balloon with the lyophilisate in powder form using an eSTAT process, wherein the active agent coated on the balloon comprises a macrolide immunosuppressive drug in crystalline form present on an exterior surface of the coating. - View Dependent Claims (20)
-
Specification